Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial is a phase 3, randomised interventional study registered as NCT06096844 by National Cancer Institute (NCI), with a registry enrolment figure of 304 participants, started 2024-07-19 and due to reach its primary completion in 2039-04-01. Interventions recorded: Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Positron Emission Tomography; Questionnaire Administration. Conditions listed: Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "* Patient must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with PD-L1 Tumor Proportion Score (TPS) range of 1-49%". Sites: United States. No results are recorded here; the registry entry is the source.